Tarsus Pharmaceuticals Inc (NASDAQ:TARS) — Market Cap & Net Worth
Market Cap & Net Worth: Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) has a market capitalization of $2.56 Billion ($2.56 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5287 globally and #1766 in its home market, demonstrating a 3.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tarsus Pharmaceuticals Inc's stock price $59.54 by its total outstanding shares 43023959 (43.02 Million). See capital reinvestment ratio of Tarsus Pharmaceuticals Inc to understand how much of operating cash flow is reinvested back into capital assets.
Tarsus Pharmaceuticals Inc Market Cap History: 2020 to 2026
Tarsus Pharmaceuticals Inc's market capitalization history from 2020 to 2026. Data shows growth from $1.78 Billion to $2.56 Billion (20.14% CAGR).
Index Memberships
Tarsus Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.47 Trillion | 0.10% | #136 of 976 |
|
NASDAQ Composite
IXIC
|
$39.70 Trillion | 0.01% | #606 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.73 Trillion | 0.15% | #88 of 263 |
Weight: Tarsus Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tarsus Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tarsus Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
7.80x
Tarsus Pharmaceuticals Inc's market cap is 7.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.78 Billion | $33.43 Million | -$26.81 Million | 53.19x | N/A |
| 2021 | $968.04 Million | $57.03 Million | -$13.83 Million | 16.98x | N/A |
| 2022 | $630.73 Million | $25.82 Million | -$62.09 Million | 24.43x | N/A |
| 2023 | $871.24 Million | $17.45 Million | -$135.89 Million | 49.94x | N/A |
| 2024 | $2.38 Billion | $182.95 Million | -$115.55 Million | 13.02x | N/A |
| 2025 | $3.52 Billion | $451.36 Million | -$66.42 Million | 7.80x | N/A |
Competitor Companies of TARS by Market Capitalization
Companies near Tarsus Pharmaceuticals Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Tarsus Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #537 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #556 globally with a market cap of $47.90 Billion USD ( ₩70.69 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $481.70 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $738.34 |
| #537 | Argen-X | BR:ARGX | $49.55 Billion | €746.60 |
| #556 | Samsung Biologics Co Ltd | KO:207940 | $47.90 Billion | ₩1527000.00 |
Tarsus Pharmaceuticals Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Tarsus Pharmaceuticals Inc's market cap moved from $1.78 Billion to $ 2.56 Billion, with a yearly change of 20.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.56 Billion | -27.28% |
| 2025 | $3.52 Billion | +47.88% |
| 2024 | $2.38 Billion | +173.43% |
| 2023 | $871.24 Million | +38.13% |
| 2022 | $630.73 Million | -34.84% |
| 2021 | $968.04 Million | -45.56% |
| 2020 | $1.78 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 31st, 2026 the market cap of Tarsus Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.56 Billion USD |
| MoneyControl | $2.56 Billion USD |
| MarketWatch | $2.56 Billion USD |
| marketcap.company | $2.56 Billion USD |
| Reuters | $2.56 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more